1
|
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Bjøro T, Wentzel-Larsen T, Dahl O. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer 2013; 107:1833-9. [PMID: 23169336 PMCID: PMC3504949 DOI: 10.1038/bjc.2012.471] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background: The objective of this study was to assess markers of spermatogenesis in long-term survivors of testicular cancer (TC) according to treatment, and to explore correlations between the markers and associations with achieved paternity following TC treatment. Methods: In 1191 TC survivors diagnosed between 1980 and 1994, serum-follicle stimulating hormone (s-FSH; n=1191), s-inhibin B (n=441), and sperm counts (millions per ml; n=342) were analysed in a national follow-up study in 1998–2002. Paternity was assessed by a questionnaire. Results: At median 11 years follow-up, 44% had oligo- (<15 millions per ml; 29%) or azoospermia (15%). Sperm counts and s-inhibin B were significantly lower and s-FSH was higher after chemotherapy, but not after radiotherapy (RT), when compared with surgery only. All measures were significantly more abnormal following high doses of chemotherapy (cisplatin (Cis)>850 mg, absolute cumulative dose) compared with lower doses (Cis ⩽850 mg). Sperm counts were moderately correlated with s-FSH (−0.500), s-inhibin B (0.455), and s-inhibin B : FSH ratio (−0.524; all P<0.001). All markers differed significantly between those who had achieved post-treatment fatherhood and those with unsuccessful attempts. Conclusion: The RT had no long-term effects on the assessed markers of spermatogenesis, whereas chemotherapy had. At present, the routine evaluation of s-inhibin B adds little in the initial fertility evaluation of TC survivors.
Collapse
Affiliation(s)
- M Brydøy
- Section of Oncology, Institute of Medicine, University of Bergen, Bergen N-5021, Norway.
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Wanderas E, Fossa S, Tretli S, Klepp O. Toxicity in long-term survivors after adriamycin containing chemotherapy of malignant germ-cell tumors. Int J Oncol 2012; 4:681-8. [PMID: 21566977 DOI: 10.3892/ijo.4.3.681] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In order to assess overall treatment-induced long-term morbidity after high-dose adriamycin-based chemotherapy +/- radiotherapy, clinically significant toxicity was studied in survivors after treatment of advanced germ-cell cancer who had received adriamycin-containing chemotherapy before cisplatin became available in Norway. Most of the patients were also irradiated. The study comprises 47 patients with advanced germ-cell cancer who survived for at least 5 years after chemotherapy containing adriamycin (VACAM: vincristine, adriamycin, cyclophosphamide, actinomycin-D and medroxyprogesterone acetate) as part of their primary systemic treatment (before 1978) or as maintenance chemotherapy after initial cisplatin-based cytotoxic treatment (after 1978). Thirty-two patients also had radiotherapy. The median follow-up was 12.3 years. Forty-one events of late toxicities were recorded in 25 patients, 37 of these were observed after combined radiotherapy and chemotherapy. The most frequent late side effects were cardiotoxicity, gastrointestinal toxicity and neurological disorders observed in 7, 12 and 8 patients, respectively. Three patients who were irradiated to the cardiac region, died of heart failure. Secondary solid cancer developed in 7 patients after a median follow-up of 10.5 years (relative risk 4.8, 95% confidence interval 1.9 to 9.9). In a historical perspective high-dose adriamycin-containing combination chemotherapy if applied with cyclophosphamide and/or radiotherapy, may occasionally be curative in selected patients with advanced germ cell tumours, but leads to an unacceptable high incidence of severe cardiac, gastrointestinal and neurological late side effects. The present follow-up study highlights that such treatment should be avoided in the curatively intended treatment of cancer patients and emphasizes the need of long-term follow-up studies in surviving cancer patients.
Collapse
|
3
|
Kristiansen W, Andreassen K, Karlsson R, Aschim E, Bremnes R, Dahl O, Fosså S, Klepp O, Langberg C, Solberg A, Tretli S, Adami HO, Wiklund F, Grotmol T, Haugen T. Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case–parent triad study in a Norwegian–Swedish population. Hum Reprod 2012; 27:1525-35. [DOI: 10.1093/humrep/des075] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
|
4
|
Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes R, Klepp O. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 2010; 21:1858-1863. [DOI: 10.1093/annonc/mdq026] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Olofsson S, Dahl O, Jerkeman M, Cohn-Cedermark G, Klepp O, Stierner U, Törnblom M, Wahlqvist R, Cavallin-Ståhl E. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5015 Background: From July 1995 to December 2003, 602 adult patients from Sweden and Norway with metastatic testicular NSGCT were included in a population-based multicenter SWENOTECA protocol with strict guidelines for staging, treatment and follow-up. Methods: The basic strategy of this protocol was to individualize treatment according to AFP and β-HCG decline (t1/2). Satisfactory response to treatment was defined as a t½ for AFP ≤ 7 days and/or β-HCG ≤ 3 days. Initial treatment for all patients was 2 courses of standard BEP. Tumor markers were analyzed once a week during treatment. Patients with satisfactory response went on with BEP while patients with unsatisfactory t1/2 received intensified treatment in two steps with addition of ifosfamide (BEP-if/PEI) in step 1. If still unsatisfactory response the treatment was intensified according to step 2 involving high-dose chemotherapy with stem cell rescue. Postchemotherapy surgery was performed according to protocol guidelines. Results: 99,7% (602 of 604) of all patients with metastatic testicular NSGCT in the population were included in the protocol. Median FU was 72 months. 75% of the patients were treated with BEP, median 4 courses, without intensification, 19% according to intensification step 1 and 6% according to intensification step 2. Five year progression free survival (PFS), cancer specific survival (CSS) and overall survival (OS) grouped according to IGCCCG prognostic score are given in the Table below. There was no significant difference in PFS between the good and intermediate risk group. Death due to all causes was 10,1% (n=61) and treatment related deaths were 1,3 % (n=8). Conclusions: Our results, in a population based patient material, with individualized treatment based on tumor marker decline, are highly encouraging in all risk groups, but most notably in the intermediate risk group. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Olofsson
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - O. Dahl
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - M. Jerkeman
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - G. Cohn-Cedermark
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - O. Klepp
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - U. Stierner
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - M. Törnblom
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - R. Wahlqvist
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - E. Cavallin-Ståhl
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | | |
Collapse
|
6
|
Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2008; 2:128-37. [PMID: 18792787 DOI: 10.1007/s11764-008-0054-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2008] [Accepted: 04/07/2008] [Indexed: 11/26/2022]
Abstract
INTRODUCTION We examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk of >or=5% for developing a fatal cardiovascular event qualify for high-risk status. METHODS One thousand one hundred thirty-four TC survivors treated 1980-1994 participated in this study (1998-2002). Patients were categorised in four treatment groups: surgery (n = 225), radiotherapy (n = 445), and two chemotherapy groups: cumulative cisplatin dose <or=850 mg (n = 375) and >850 mg (cis>850, n = 89). Patients with cardiovascular disease, diabetes or SCORE >or=5% constituted a high-risk group, and those with SCORE >1% an intermediate/high risk group. RESULTS Age-adjusted mean SCORE was 0.93% for the surgery group. In comparison, chemotherapy treated patients had significantly higher SCORE (1.07%, p = 0.01). Only 15% of patients were scored to be at high-risk, while 53% qualified for the intermediate/high risk group. Patients in the cis>850 group had increased odds for having intermediate/high risk, compared with the surgery group (OR 3.4, 95% CI 1.3-8.7). Only 23 cardiovascular events had occurred since the testicular cancer diagnosis. CONCLUSION The SCORE model indicates that patients treated with cisplatin-based chemotherapy have a significantly increased future risk of a fatal cardiovascular event. IMPLICATIONS FOR CANCER SURVIVORS TC survivors should be followed regularly with respect to cardiovascular risk profile beyond the routine 10-year clinical follow-up.
Collapse
Affiliation(s)
- H S Haugnes
- Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Tandstad T, Dahl O, Cohn Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes R, Klepp O. 4512 POSTER Risk-adapted treatment in clinical stage 1 (CS1), non-seminomatous germ cell testicular cancer (NSGCT). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71143-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Svartberg J, Wilsgaard T, Bremnes RM. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18:241-8. [PMID: 17060482 DOI: 10.1093/annonc/mdl372] [Citation(s) in RCA: 147] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND A possible explanation of the excess cardiovascular risk in testicular cancer (TC) survivors is development of metabolic syndrome. The association between metabolic syndrome and TC treatment is examined in long-term survivors. PATIENTS AND METHODS In a national follow-up study (1998-2002), 1463 TC survivors (diagnosed 1980-1994) participated. Patients >60 years were excluded in the present study, leaving 1135 patients eligible. The patients were divided in four treatment groups: surgery (n = 225); radiotherapy (n = 446) and two chemotherapy groups: cumulative cisplatin dose (Cis) <or=850 mg (n = 376) and Cis >850 mg (n = 88). A control group consisted of 1150 men from the Tromsø Population Study. Metabolic syndrome was defined according to a modified National Cholesterol Education Program definition. RESULTS Both chemotherapy groups had increased odds for metabolic syndrome compared with the surgery group, highest for the Cis >850 group [odds ratio (OR) 2.8, 95% confidence interval (CI) 1.6-4.7]. Also, the Cis >850 group had increased odds (OR 2.1, 95% CI 1.3-3.4) for metabolic syndrome compared with the control group. The association between metabolic syndrome and the Cis >850 group was strengthened after adjusting for testosterone, smoking, physical activity, education and family status. CONCLUSION TC survivors treated with cisplatin-based chemotherapy have an increased risk of developing metabolic syndrome compared with patients treated with other modalities or with controls.
Collapse
Affiliation(s)
- H S Haugnes
- Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Norway.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist E, Dahl O, Fossa SD. Self-reported paresthesias, Raynaud’s phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TC) survivors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4547] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4547 Background: Persisting side-effects of treatment may impair the well-being of TC survivors. The aim of this study was to assess long-term Raynaud’s phenomena, oto-, and neurotoxicity related to prior therapy. Methods: A follow-up survey was conducted in men treated for TC 1980–1994 in Norway. The 1319 eligible responders had a median follow-up time of 11 years (range 4–21) and were allocated to four separate treatment groups: Surgery (Surg), Radiotherapy (Rt), and chemotherapy (Cisplatin [Cis] ≤ 850 mg and Cis > 850 mg). The questionnaire included six items assessing the relevant toxicities. The responders’ scores were dichotomized [minor (“not at all” or “a little”) vs. major (“quite a bit” or “very much”)] and analyzed by logistic regression with Surg as reference. Results: The proportion of cases (%) reporting major symptoms and the corresponding Odds ratios (OR) varied significantly between treatment groups ( table ). Rt was not statistically significantly different from Surg for any symptom, but showed a trend for higher scores of paresthesias in the feet. Cis > 850 mg differed significantly for all symptoms with major symptoms reported by 25–49% with the highest OR (8.1) for Raynaud’s phenomena in hands. Apart from Raynaud’s phenomena, paresthesias in feet were the only symptom significantly different in Cis < 850 mg compared to Surg. Conclusions: Toxicities induced by cisplatin-based chemotherapy persist in many TC survivors. A cold climate may contribute to the high perception of Raynaud’s phenomena in Norwegian TC survivors. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Brydoy
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - J. Oldenburg
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - O. Klepp
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - R. M. Bremnes
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - E. Wist
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - O. Dahl
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - S. D. Fossa
- Haukeland University Hospital, Bergen, Norway; Rikshospital-Radiumhospital Trust, Oslo, Norway; St.Olavs University Hospital, Trondheim, Norway; University Hospital of Northern Norway, Tromso, Norway; Ullevål University Hospital, Oslo, Norway; University of Bergen, Bergen, Norway; Norwegian Radium Hospital, Oslo, Norway
| |
Collapse
|
10
|
Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23:4980-90. [PMID: 16051950 DOI: 10.1200/jco.2005.06.882] [Citation(s) in RCA: 109] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To evaluate blood pressure and body mass index (BMI) in long-term survivors of testicular cancer (TC) treated with different modalities. PATIENTS AND METHODS One thousand eight hundred fourteen patients treated for unilateral TC in Norway (1980 to 1994) were invited to participate in a follow-up study (1998 to 2002), including measurements of systolic blood pressure (SBP), diastolic blood pressure (DBP), and BMI. Of these patients, 1,289 patients (71%) participated in the study. The patients were categorized into four treatment groups: surgery (n = 242), radiotherapy (n = 547), and two chemotherapy groups, cumulative cisplatin dose < or = 850 mg (n = 402) and cumulative cisplatin dose more than 850 mg (n = 98). A control group consisted of healthy males from the Tromsø Population Study (n = 2,847). RESULTS At diagnosis, age-adjusted regression analyses showed no differences between the treatment groups for any variables. After a median follow-up time of 11.2 years, age-adjusted SBP and DBP were significantly higher for both chemotherapy groups compared with the surgery group. Chemotherapy-treated patients had increased odds for hypertension at follow-up compared with the surgery group, and the odds were highest for the cisplatin more than 850 mg group (odds ratio = 2.4; 95% CI, 1.4 to 4.0). The cisplatin more than 850 mg group had a significantly higher 10-year BMI increase and a higher prevalence of obesity at follow-up than the surgery group. Compared with healthy controls, chemotherapy-treated patients had, at follow-up, increased SBP, increased DBP, excessive BMI increase, and a higher prevalence of hypertension. CONCLUSION Five to 20 years after therapy, cured TC patients treated with cisplatin-based chemotherapy had significantly higher levels of blood pressure, a higher prevalence of hypertension, and an excessive weight gain compared with patients treated with other modalities and compared with healthy controls.
Collapse
Affiliation(s)
- H Sagstuen
- Department of Oncology, Institute of Clinical Medicine, University of Tromsø, N-9037 Tromsø, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist E, Svartberg J, Wilsgaard T, Bremnes RM. Metabolic syndrome in long-term testicular cancer survivors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Sagstuen
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - N. Aass
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - S. D. Fosså
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - O. Dahl
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - O. Klepp
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - E. Wist
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - J. Svartberg
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - T. Wilsgaard
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| | - R. M. Bremnes
- Univ of Tromsø, Tromsø, Norway; Norwegian Radium Hosp, Oslo, Norway; Univ Hosp of Haukeland, Bergen, Norway; St. Olavs Hosp, Trondheim, Norway; Univ Hosp of Ullevål, Oslo, Norway; Univ Hosp of Tromsø, Tromsø, Norway
| |
Collapse
|
12
|
Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PHM, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GON, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377-99. [PMID: 15319245 DOI: 10.1093/annonc/mdh301] [Citation(s) in RCA: 380] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of > or = 99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception.
Collapse
Affiliation(s)
- H J Schmoll
- European Germ Cell Cancer Consensus Group, Martin-Luther-University, Department of Hematology/Oncology, Halle, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Brydoy M, Fossa S, Klepp O, Wist E, Bremnes R, Dahl O. Post-treatment paternity in testicular cancer survivors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Brydoy
- University of Bergen, Bergen, Norway; University of Oslo, Oslo, Norway; Norwegian University of Science and Technology, Trondheim, Norway; University Hospital of North Norway, Tromsoe, Norway
| | - S. Fossa
- University of Bergen, Bergen, Norway; University of Oslo, Oslo, Norway; Norwegian University of Science and Technology, Trondheim, Norway; University Hospital of North Norway, Tromsoe, Norway
| | - O. Klepp
- University of Bergen, Bergen, Norway; University of Oslo, Oslo, Norway; Norwegian University of Science and Technology, Trondheim, Norway; University Hospital of North Norway, Tromsoe, Norway
| | - E. Wist
- University of Bergen, Bergen, Norway; University of Oslo, Oslo, Norway; Norwegian University of Science and Technology, Trondheim, Norway; University Hospital of North Norway, Tromsoe, Norway
| | - R. Bremnes
- University of Bergen, Bergen, Norway; University of Oslo, Oslo, Norway; Norwegian University of Science and Technology, Trondheim, Norway; University Hospital of North Norway, Tromsoe, Norway
| | - O. Dahl
- University of Bergen, Bergen, Norway; University of Oslo, Oslo, Norway; Norwegian University of Science and Technology, Trondheim, Norway; University Hospital of North Norway, Tromsoe, Norway
| |
Collapse
|
14
|
Balteskard L, Bremnes RM, Dahl O, Klepp O, Wist E, Fossa SD. Working ability and educational level among long-term survivors of testicular cancer (TCSS) compared to a general population (GenPop). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Balteskard
- University Hospital of Northern Norway, Tromsø, Norway; University Hospital of Bergen, Bergen, Norway; St Olav's Hospital, Trondheim, Norway; Ulleval University Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - R. M. Bremnes
- University Hospital of Northern Norway, Tromsø, Norway; University Hospital of Bergen, Bergen, Norway; St Olav's Hospital, Trondheim, Norway; Ulleval University Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - O. Dahl
- University Hospital of Northern Norway, Tromsø, Norway; University Hospital of Bergen, Bergen, Norway; St Olav's Hospital, Trondheim, Norway; Ulleval University Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - O. Klepp
- University Hospital of Northern Norway, Tromsø, Norway; University Hospital of Bergen, Bergen, Norway; St Olav's Hospital, Trondheim, Norway; Ulleval University Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - E. Wist
- University Hospital of Northern Norway, Tromsø, Norway; University Hospital of Bergen, Bergen, Norway; St Olav's Hospital, Trondheim, Norway; Ulleval University Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo, Norway
| | - S. D. Fossa
- University Hospital of Northern Norway, Tromsø, Norway; University Hospital of Bergen, Bergen, Norway; St Olav's Hospital, Trondheim, Norway; Ulleval University Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo, Norway
| |
Collapse
|
15
|
Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR. Knowledge of and attitudes toward complementary and alternative therapies. Eur J Cancer 2004; 40:529-35. [PMID: 14962719 DOI: 10.1016/j.ejca.2003.11.011] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2003] [Accepted: 11/07/2003] [Indexed: 10/26/2022]
Abstract
This study reports on oncology professionals' knowledge and attitude toward complementary and alternative medicines (CAM), classified according to their primary application as complementary or alternative methods. In June 2002, we conducted a national, multicentre survey of 828 Norwegian oncologists, nurses, clerks and therapeutic radiographers. A response rate of 61% was achieved. Only a few physicians (4%) described their reactions to alternative medicine as positive compared with nurses (33%), therapeutic radiographers (32%) and clerks (55%) (P<0.0001). Females showed a more positive view than males (33% versus 14%, P<0.0001). More participants expressed a positive attitude to complementary versus alternative medicines. Most respondents regarded healing by hand or prayer, homeopathy, and Iscador (mistletoe) as alternative therapies. In contrast, most respondents classified acupuncture, meditation, reflexology, music/art-therapy, aromatherapy and massage as complementary therapies. This survey demonstrates major differences, by gender as well as oncology health profession in views about and the classification of various CAM methods.
Collapse
Affiliation(s)
- T Risberg
- Department of Oncology, University Hospital of Tromsø, N-9038 Tromsø, Norway.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E. Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer 2004; 12:312-8. [PMID: 14767750 DOI: 10.1007/s00520-004-0590-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2003] [Accepted: 01/12/2004] [Indexed: 10/26/2022]
Abstract
GOALS OF WORK It is well documented that an increasing proportion of cancer patients today use complementary and alternative medicine, mostly alongside conventional therapies. This study investigates the use of complementary and alternative medicine among oncology health workers and the reported effects. PATIENTS AND METHODS In June 2002, we conducted a national multicentre survey including 828 Norwegian oncologists, nurses, clerks and therapeutic radiographers. The response rate was 61.5%. MAIN RESULTS We found that females were more often users of both complementary and alternative methods than males (39% versus 15% and 47% versus 17%) and that few oncologists had tried such treatments compared to nurses, therapeutic radiographers and clerks (20/12% versus 50/40%, 41/33%,and 31/50%). Interestingly, the majority of those who had tried unconventional methods reported some or very good effects. Acupuncture, homeopathy, aromatherapy and massage were the most popular therapies. Sub-group analyses including only oncologists showed that female physicians were more often users of both complementary and alternative methods compared to males (33% versus 12%, 25% versus 3%). Moreover, participants below the age of 35 years and Christians more often reported use. CONCLUSIONS This survey demonstrates that significant proportion of oncology health workers in Norway have used non-proven therapies and that most have had a positive experience. Differences in use is highly dependent on gender, profession, age and religion.
Collapse
Affiliation(s)
- A Kolstad
- Department of Oncology, The Norwegian Radium Hospital, 0310, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
The aim of this study was to estimate the level of physical activity (LPA) in a large cohort of testicular cancer survivors (TCSs) and compare these results with observations from men in the same age range in the general population (GenPop). We also wanted to identify parameters that influenced physical activity. The study populations consisted of 1276 TCSs treated with surgery, radiotherapy or chemotherapy with or without surgery (mean observation time was 12 years), and 20391 male inhabitants from a Norwegian county (GenPop). All completed a question investigating two sub-levels of physical activity. The logistic regression analysis adjusting for different covariates, showed significantly more physically active men among the TCSs compared with the GenPop (43 versus 37%) (adjusted odds ratio (aOR)=1.32 (95% Confidence Interval (CI) 1.10-1.58)). The results indicate that the experience of testicular cancer increases rather than reduces the LPA in TCSs, independent of treatment given.
Collapse
Affiliation(s)
- L Thorsen
- Department and Psychosocial Oncology and Rehabilitation, The Norwegian Radium Hospital, University of Oslo, Oslo 0310, Norway.
| | | | | | | | | | | | | |
Collapse
|
18
|
Widmark A, Fosså SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61:145-51. [PMID: 12559286 DOI: 10.1016/s0090-4295(02)02107-6] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVES To examine the development of antiandrogen-induced gynecomastia and breast tenderness in the first 253 patients in a randomized Scandinavian trial (SPCG-7/SFUO-3) with a 12-month complete follow-up evaluation performed by both doctors and patients. METHODS In this study, the treating doctor and patient decided whether prophylactic irradiation (RT) of the breast should be given to prevent antiandrogen-induced gynecomastia. At each visit, the doctor evaluated the occurrence of gynecomastia and breast tenderness. Questions about gynecomastia and breast tenderness were also included in the study quality-of-life questionnaire (Prostate Cancer Symptom Scale). RESULTS Mammary RT with mostly single fraction (12 to 15 Gy) electrons was given to 174 (69%) of the 253 evaluated patients. At the 1-year follow-up visit, the doctor evaluations indicated some form of gynecomastia in 71% and 28% (P <0.001) of the nonirradiated (no-RT) and irradiated (RT) patients, respectively. The patient evaluations at 1 year showed some form of breast enlargement in 78% and 44% (P <0.001) of the no-RT and RT patients, respectively. The doctors reported some form of breast tenderness at 1 year in 75% and 43% (P <0.001) of the no-RT and RT patients, respectively. The patient evaluations of breast tenderness show an expected significant increase in the RT arm at the 3-month follow-up, which was probably due to skin reactions. At 1 year, significantly more patients who marked "very much" on the Prostate Cancer Symptom Scale were seen in the no-RT group. A weak correlation between the doctors' and patients' detection of breast problems was observed. CONCLUSIONS The results show that, with high significance, prophylactic RT of the breast decreases the risk of antiandrogen-induced gynecomastia and breast tenderness.
Collapse
Affiliation(s)
- A Widmark
- Department of Oncology, Umeå University, Umeå, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
OBJECTIVES To establish guidelines for the diagnosis, staging, treatment and follow-up of germ cell testicular cancer. METHODS A search of published work was conducted using Medline. Highly evidence-based articles were selected and their findings analysed by the members of the Oncological Urology Working Group of the EAU. Testis cancer is rare and affects young men in their 3rd and 4th decades of life. The majority of these tumours are derived from germ cells (seminomatous and non-seminoma germ cell testicular cancer), and more than 50% of patients are diagnosed with stage I disease. Epidemiological, pathological and clinical risk factors are well established. The tumour, node, metastasis (TNM) staging system is endorsed, and for metastatic disease a recently devised prognostic-factor-based staging system has proven to be useful. Staging assessment includes pre- and post-orchiectomy marker levels, pathology of the testis, and nodal and visceral status. Following orchiectomy, treatment depends on the tumour type, pathological risk factors for stage I disease and clinical prognostic factors for advanced disease. The cure rate is excellent for disease stages I and II, irrespective of the treatment adopted. However, the pattern of relapse (rate, timing and site) is highly influenced by therapeutic policy. For metastatic disease, survival depends on clinical prognostic factors and treatment. Follow-up schedules are tailored according to stage, tumour type and post-orchiectomy treatment schedules. CONCLUSIONS Excellent cure rates are achieved for early-stage germ cell testis tumours following accurate staging at diagnosis. Satisfactory survival rate can be achieved in advanced metastatic disease using a multidisciplinary therapeutic approach. Follow-up schedules vary, depending on the pathology and stage of the primary tumour and on the treatment policy adopted following orchiectomy.
Collapse
Affiliation(s)
- M P Laguna
- Department of Urology, UMC St Radboud, Nijmegen, The Netherlands.
| | | | | | | | | | | |
Collapse
|
20
|
Widmark A, Damber L, Fosså S, Lundmo P, Damber J, Klepp O. 1010 Does prophylactic radiotherapy prevent antiandrogen induced gynecomastia? Evaluation of patients in the randomized scandinavian trial SPCG7/SFUO-3. Int J Radiat Oncol Biol Phys 1999. [DOI: 10.1016/s0360-3016(99)90236-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
21
|
Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tørnblom M, Småland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Ståhl E. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997; 33:1038-44. [PMID: 9376184 DOI: 10.1016/s0959-8049(97)00041-5] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
250 patients with clinical stage 1 non-seminomatous germ cell tumours of the testis (NSGCT 1) were included into a prospective multicentre protocol during 1990-1994 and treated according to three risk strata: patients without tumour cell invasion of vascular structures in the testis (VASC-) and elevated serum AFP levels (AFP+) at orchiectomy were considered low risk (LR) and only observed closely. VASC- and AFP- or VASC+ and AFP+ patients were presumed intermediate risk (IR) and pathologically staged (PS) by retroperitoneal lymph node dissection (RPLND). VASC+ and AFP-patients were regarded as high risk (HR) and received adjuvant chemotherapy (PEB x 3). At a median observation time of 40 (7-68) months, all patients were alive and without evidence of active germ cell cancer. The actuarial relapse rate in the 106 LR patients was 22%, and 70% (14/20) had elevated serum tumour markers at relapse. One of 32 (3%) HR patients relapsed with a resectable retroperitoneal mature teratoma despite adjuvant chemotherapy. Only 14% of the 99 IR patients who underwent RPLND had PS2 disease, and the actuarial relapse rate in 85 PS1 patients was 18%. This multicentre study demonstrated that excellent therapeutic outcome is possible when 18 comparatively small urological and oncological centres follow a strict and formal cancer care programme. The useful prognostic effect of VASC was once again verified. Pathological staging by RPLND in NSGCT1 is, in our opinion, not necessary, with presumed low-risk patients offered surveillance and high-risk patients offered adjuvant chemotherapy.
Collapse
Affiliation(s)
- O Klepp
- Department of Oncology, Trondheim University Hospital, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Kaasa S, Klepp O, Hagen S, Wist E, Kvinnsland S. Treatment intention in hospitalized cancer patients in oncological wards in Norway: a national survey. Cancer Treat Rev 1996; 22 Suppl A:33-9. [PMID: 8625347 DOI: 10.1016/s0305-7372(96)90061-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Clinicians often do not agree whether a treatment is given with a palliative or curative intent. A common clear definition does not exist. This study has assessed the usefulness of dividing the goal of treatment into three distinct categories: curative treatment; palliative, symptom preventive treatment; and palliative, symptom relieving treatment. In a cross-sectional study among all cancer centres in Norway, a total of 629 patients were included into the study. Of these patients, 60% received palliative treatment, with an equal distribution between symptom preventive and symptom relieving. The definitions were found easy to use by the physicians. It gave important information of differences between cancer diagnosis with respect to the number of patients receiving palliative treatment. In order to refine the classification system, the authors will, in future studies, include a fourth category, life prolonging treatment, which is located between curative and palliative treatment with respect to treatment intensity.
Collapse
Affiliation(s)
- S Kaasa
- Department of Oncology, Trondheim University Hospital, Norway
| | | | | | | | | |
Collapse
|
23
|
Klepp O. 903 Risk-adapted treatment of clinical stage 1 (CS1) nonseminoma testis cancer (NSTC). Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96152-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Klepp O. [Testicular cancer--Norway among the countries with the highest frequency. Regional multicenter cooperation is effective]. Tidsskr Nor Laegeforen 1995; 115:1713-4. [PMID: 7785027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Affiliation(s)
- O Klepp
- Kreftavdelingen, Regionsykehuset i Trondheim
| |
Collapse
|
25
|
Holdener EE, Clavel M, Sessa C, ten Bokkel Huinink W, Siegenthaler P, Ludwig C, Klepp O, Renard G, Decoster G, Pinedo HM. Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study. Eur J Cancer 1994; 30A:394-5. [PMID: 8204365 DOI: 10.1016/0959-8049(94)90262-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Anaxirone, a rationally synthesised triepoxide derivative, was given to 46 patients with metastatic colorectal cancer. Good risk patients received 800 mg/m2 as a rapid intravenous injection every 4 weeks, whereas poor risk patients received 650 mg/m2. Of 46 patients, 45 were evaluable for toxicity and 42 for efficacy analysis. There were 37/45 patients with poor risk, showing no difference in toxicity as compared to good risk patients. The major toxic effect was myelosuppression with 34% of all patients experiencing grade 3 or 4 leucopenia; thrombocytopenia was less frequent. Locoregional phlebitis occurred in 66% of the patients. There was no objective tumour response to anaxirone in 42 evaluable patients. Only 4 patients achieved stabilisation of the disease lasting maximally up to 248 days. Anaxirone is inactive in metastatic colorectal cancer.
Collapse
Affiliation(s)
- E E Holdener
- Division of Oncology-Immunology/Clinical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Haaverstad R, Myrvold HE, Klepp O, Sundstrøm S, Aase S, Langmark F. [Treatment of anal cancer in Trøndelag]. Tidsskr Nor Laegeforen 1993; 113:3454-7. [PMID: 8273074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
We have retrospectively examined the medical records and prospectively studied the survival of 43 patients (37 women and six men) treated for anal cancer in the Trøndelag region of Norway during the period 1970-89. During this period, different strategies were used, ranging from primary surgery to combined chemo-radiotherapy and sphincter saving therapy. 20 patients were treated with surgery alone, nine patients first with surgery and postoperatively with irradiation because the surgery was non-radical (histologic), and 14 patients with combined chemo- and radiotherapy. The five year cancer ani-specific survival in the whole group is 69%. The predicted five year survival in the chemo-radiotherapy group is 90% versus 61% in the group treated with surgery. Primary chemotherapy combined with radiotherapy should be the preferred treatment for carcinoma of the anal canal.
Collapse
|
27
|
Klepp O. Na 2TiOS 2 — Ein Oxothiotitanat(IV) mit unendlichen Tetraederketten / Na 2TiOS 2 — An Oxothiotitanate(IV) with Infinite Tetrahedral Chains. Zeitschrift für Naturforschung B 1993. [DOI: 10.1515/znb-1993-0501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Colourless single crystals of Na2TiOS2 were obtained by a fusion reaction of a stoichiometric mixture of Na2S, Na2SO3, titanium-powder and elemental sulphur. Na2TiOS2 is monoclinic, space group P21/c with a = 6.861(3), b = 13.610(9), c = 5.733(9) Å, β = 113.24(2)°, Ζ = 4. The crystal structure (R = 0.032, 811 observations, 55 variables) is characterized by infinite anionic chains of TiO2S2-tetrahedra sharing the oxygen atoms (d̄Ti-o = 1.842 Å, d̄Ti-s = 2.227 Å,
Ti—O—Ti = 134.3°). The chains are separated from each other by octahedrally coordinated Na+ ions. The structure may be considered as a quaternary variant of the Na2GeS3-structure type.
Collapse
Affiliation(s)
- O. Klepp
- Abt. für Allgemeine und Anorganische Chemie, Johannes-Kepler-Universität, Altenbergerstraße 69, A-4040 Linz, Österreich
| |
Collapse
|
28
|
Wanderås EH, Tretli S, Klepp O, Fossà SD. Clinical long-term toxicity after intensive cytotoxic treatment for malignant germ-cell tumors (GCT). Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91978-t] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Gundersen S, Kvinnsland S, Klepp O, Lund E, Hannisdal E, Høst H. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group. Eur J Cancer 1992; 28:390-4. [PMID: 1534248 DOI: 10.1016/s0959-8049(05)80060-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
In a randomised study 142 patients with advanced oestrogen-receptor-negative breast cancer in the tumour tissue received chemotherapy alone or chemotherapy combined with high doses (1000 mg daily) of oral medroxyprogesterone acetate (HD-MPA). Of the 126 fully evaluable for response, the response rates were 46% for chemotherapy alone and 73% for chemotherapy with HD-MPA (P = 0.005). There was no significant difference with regard to duration of response. Of the 138 patients evaluable for survival and toxicity, survival was shorter in the combined treatment group; median survival of 9 versus 13 months (P less than 0.05). Considerable toxicity was seen from HD-MPA, especially weight gain and fluid retention. The present study provides evidence that in concordance with preclinical studies an interaction between chemotherapy and HD-MPA may exist in breast cancer normally resistant to hormone therapy. The side-effects from MPA were substantial, however, and the survival data are of great concern.
Collapse
Affiliation(s)
- S Gundersen
- Department of Oncology, Norwegian Radium Hospital, Oslo
| | | | | | | | | | | |
Collapse
|
30
|
Abstract
The clinical significance of neuron-specific enolase (NSE) as a tumour marker was evaluated in 54 patients with seminoma. Before orchiectomy NSE was elevated in six out of 21 patients with stage I seminoma and 11 out of 16 patients with metastases. After orchiectomy NSE normalised in all evaluated stage I cases, but was still elevated in six out of 12 patients with metastatic disease. NSE monitored the effect of cisplatin-based chemotherapy in patients with metastases. In some patients, increased serum NSE was found together with raised levels of human choriogonadotropin (HCG) and lactate dehydrogenase (LDH), while in others only NSE was elevated. No false positive NSE values were observed. NSE seems to be a clinically worthwhile serum tumour marker for monitoring seminoma patients, with a sensitivity and specificity of the same order as HCG.
Collapse
Affiliation(s)
- S D Fosså
- Department of Medical Oncology, Norwegian Radium Hospital, Oslo
| | | | | |
Collapse
|
31
|
Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, Baldetorp L, Ahlström S, Fosså SD. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991; 9:818-26. [PMID: 1707957 DOI: 10.1200/jco.1991.9.5.818] [Citation(s) in RCA: 123] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Between 1981 and 1986, 200 consecutive patients with metastatic nonseminomatous testicular cancer were entered into the Swedish Norwegian Testicular Cancer (SWENOTECA) project from 14 hospitals. The treatment plan was four chemotherapy cycles (cisplatin, vinblastine, and bleomycin) followed by surgical resection of residual tumor masses. After a median observation time of 75 months, the overall 5-year survival rate was 82%. In a univariate analysis, the following parameters influenced the prognosis significantly: the extent of the disease (Medical Research Council [MRC] grouping); the prechemotherapy levels of serum alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH); the patients' age; the presence of extrapulmonary hematogeneous metastases; and/or particularly large lymph node metastases. Patients fared better when more than 3 weeks elapsed between orchiectomy and start of chemotherapy as compared with those who were treated within this interval. The place of treatment (a large oncology unit v smaller units) also represented a significant prognostic factor for patients with large-volume (LV) and very-large-volume (VLV) disease combined. Multivariate analysis (Cox regression proportional hazards model) performed in all 193 assessable patients showed the following adverse prognostic factors: high-volume metastatic burden, age older than 35 years, prechemotherapy AFP greater than 500 micrograms/L and/or HCG greater than 1,000 U/L, and an interval between orchiectomy and start of chemotherapy of less than 3 weeks. The place of treatment also significantly influenced the final outcome. If patients with LV and VLV disease were combined, the presence of two of the following risk factors represented an additional prognostic factor: AFP greater than 1,000 micrograms/L, HCG greater than 10,000 U/L, liver metastases, brain metastases, bone metastases, retroperitoneal tumor greater than or equal to 10 cm, and mediastinal tumor greater than or equal to 5 cm.
Collapse
Affiliation(s)
- N Aass
- Department of Medical Oncology, Norwegian Radium Hospital, Oslo
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Two phase 2 clinical trials of an oral superparamagnetic contrast agent for enhancement on magnetic resonance images of the intestine were performed. In trial 1, 31 male patients with cancer of the testis underwent follow-up examinations of the abdomen at 0.5 and 1.5 T after oral administration of magnetic particles. In trial 2, 31 female patients with pelvic and lower abdominal disease were examined at 1.5 T after administration of the contrast material. The patients each ingested 800 mL of contrast material over approximately 2 hours. Concentrations of 0.25 and 0.5 g/L did not induce blurring or metallic artifacts. Distribution was homogeneous through the gastrointestinal tract. In all patients, a loss of signal intensity was observed on proton density-, T1-, and T2-weighted images. The diagnostic information from postcontrast images in trial 2 was greater in 16 patients (52%). Contrast enhancement was independent of field strength; no major side effects were observed. Artifacts from moving bowels were less troublesome, and delineation of intraabdominal and pelvic organs was better with the use of oral magnetic particles.
Collapse
Affiliation(s)
- P A Rinck
- MR Center, University of Trondheim, Norway
| | | | | | | | | | | | | |
Collapse
|
33
|
Klepp O, Olsson AM, Ous S, Nilsson S, Høisaether PA, Tveter K. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project. Scand J Urol Nephrol 1991; 25:179-90. [PMID: 1658924 DOI: 10.3109/00365599109107944] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
During a 5-year period, 588 consecutive patients with nonseminomatous testicular germ cell cancer were included by 16 hospitals into the Swedish-Norwegian Testicular Cancer Project (SWENOTECA). A total of 370 (63%) had early clinical stages (CS1, CS1Mk+ and CS2A), and 345 (93%) of these patients underwent pathological staging (PS) by retroperitoneal lymph node dissection (RPLND). The overall clinical staging accuracy was 75%, with no significant difference between hospitals with low, medium or high patient accrual rate. Addition of bipedal lymphography did not improve the clinical staging accuracy compared to evaluation of the retroperitoneum by CT alone. Tumor serum markers before and close monitoring of the levels after orchiectomy gave valuable information regarding risk of retroperitoneal metastases. After a median follow-up period of 5 years 30 (13.8%) of 217 patients with PS1 disease relapsed, only 3 of them later than 18 months from the RPLND. Short orchiectomy to RPLND time interval, vascular invasion and absence of teratoma elements in the primary tumour were significant predictors of relapse in PS1 cases according to multivariate analysis. Unilateral RPLND was not associated with higher relapse rate than a bilateral procedure, but significantly reduced the risk of dry ejaculation after RPLND. None out of 122 PS2 patients who received adjuvant cisplatin-based chemotherapy after RPLND relapsed, despite the fact that 37 of them had only undergone a unilateral RPLND. Repeated CT examinations and most routine blood tests except serum alpha foeto protein (AFP), beta subunit of human chorionic gonadotropin (HCG) and lactate dehydrogenase (LD) may safely be omitted in the follow-up period for patients who have been pathologically staged with RPLND, provided that effective adjuvant chemotherapy has been given to the PS2 patients.
Collapse
Affiliation(s)
- O Klepp
- Department of Oncology, University Hospital, Trondheim, Norway
| | | | | | | | | | | |
Collapse
|
34
|
Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 1990; 17:45-50. [PMID: 2151369 DOI: 10.1007/bf01812683] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
One-hundred and seventy patients with estrogen receptor positive (greater than or equal to 10 pmol/g protein) advanced breast cancer have been treated in a prospective randomized study either with continuous tamoxifen 30 mg x 1 daily (TAM), or with TAM 30 mg x 1 daily for 8 weeks alternating with medroxyprogesterone acetate 500 mg x 2 daily for 8 weeks (TAM/HD-MPA). The response rate was 62% in the group treated with cyclic TAM/HD-MPA versus 41% in the TAM alone group (p = 0.02). There was no significant difference in duration of remissions or survival.
Collapse
Affiliation(s)
- S Gundersen
- Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Montebello, Oslo
| | | | | | | | | | | | | |
Collapse
|
35
|
Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fosså SD, Paus E. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1990; 1:281-8. [PMID: 1702312 DOI: 10.1093/oxfordjournals.annonc.a057749] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
During a 5-year period (1981-86) 588 consecutive patients with nonseminatous germ cell tumors of the testis were included into a prospective Swedish-Norwegian multicenter study (SWENOTECA) and clinically staged according to the Royal Marsden system. A total of 370 patients (63%) had early clinical stages (CS) of disease; 295 (50%) had CS1, 32 (5%) had CS1Mk+ (CS1 with pathological serum tumor marker patterns after orchiectomy) and 43 (7%) had CS2A disease. Pathological staging with retroperitoneal lymph node dissection (RPLND) of the retroperitoneum was performed in 345 (93%) of the early CS patients and 128 (37%) had pathological stage 2 (PS2) disease; 27% of the CS1, 100% of the CS1Mk+ and 66% of the CS2A patients. The overall clinical staging accuracy was 75%. All the 40 patients with pathological serum AFP and/or HCG patterns before RPLND had PS2 disease, compared to 81/282 (29%) of patients with normal marker patterns. The PS2 patients with pathological marker patterns had significantly more and larger retroperitoneal metastases than those with normal AFP and HCG values. Elevated pre-orchiectomy AFP level indicated significantly reduced risk of PS2 disease in CS1 patients, but this effect became non-significant if the CS1Mk+ and CS2A cases were included into univariate or multivariate analyses. We suggest that the 'good risk' effect of pre-orchiectomy AFP elevation for CS1 cases may be caused by a selection mechanism during the clinical staging process.
Collapse
Affiliation(s)
- O Klepp
- Department of Oncology, University Hospitals of Trondheim, Bergen, Norway
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
To evaluate the ability of proton nuclear magnetic resonance (NMR) spectroscopy to indicate the presence or absence of malignant disease, we analyzed plasma samples from 104 patients with untreated cancer of various types and from 164 healthy controls. All specimens were coded with random numbers, and the investigators were blind to patient category. A statistically significant difference (P less than 0.001) was found between the mean (+/- SD) line widths in the plasma samples from the controls (39.1 +/- 6.7 Hz) and the line widths in plasma from the patients with cancer (35.2 +/- 6.4 Hz). However, the values showed considerable overlap between the two groups. The average line widths in the 54 male (36.0 +/- 7.9 Hz) and the 110 female (40.5 +/- 5.6 Hz) controls were significantly different (P less than 0.001). Differences in the average line width were also found between 34 male controls 40 years old or older (33.9 +/- 6.5 Hz) and 20 younger men (39.6 +/- 8.8 Hz) (P = 0.008) and between 61 female controls 40 or older (38.8 +/- 5.7 Hz) and 49 younger women (42.5 +/- 4.7 Hz) (P less than 0.001). The average line widths in 36 women with cancer (35.5 +/- 6.8 Hz) and their controls matched for age and sex (39.0 +/- 6.3 Hz) were significantly different (P = 0.03) but again showed much overlap. In 29 men with cancer, the line widths were not different from those of controls matched for age and sex. We conclude that proton NMR spectroscopy is not generally reliable for the detection of cancer. Furthermore, our data demonstrate the importance of studying control groups matched for age and sex.
Collapse
Affiliation(s)
- T Engan
- Department of Oncology and Radiotherapy, Regionsykehuset i Trondheim, Norway
| | | | | | | |
Collapse
|
37
|
Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson BE, Cavallin-Ståhl E, Fosså SD, Wahlqvist L. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990; 8:509-18. [PMID: 1689773 DOI: 10.1200/jco.1990.8.3.509] [Citation(s) in RCA: 130] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Between 1981 and 1986, 279 consecutive patients with clinical stage I (CS1) nonseminomatous germ cell tumors (NSGCT) of the testis underwent pathological staging (PS) with retroperitoneal lymphadenectomy (RPLND). Patients with retroperitoneal metastases (PS2) received adjuvant chemotherapy. The median follow-up time after RPLND was 50 months (range, 30 to 90). Clinical and histopathologic features were registered prospectively and analyzed for association with risk of having PS2, relapse despite pathological stage 1 (PS1) or the combined risk of either event, metastatic disease (MET). Seventy-five (26.9%) of the patients had PS2 disease, and 30 (14.7%) of the 204 PS1 patients relapsed, indicating that at least 105 (37.6%) of this CS1 population had subclinical MET at the time of orchiectomy. Four (1.4%) of the 279 CS1 patients died of testicular cancer. Multivariate analyses showed several variables to be significantly associated with outcome for the CS1 patients; vascular invasion in primary tumor and normal preorchiectomy serum alpha-fetoprotein (Pre-AFP) level indicated PS2 disease. If Pre-AFP was excluded from the model, the absence of teratoma or yolk sac elements in the primary tumor became significant predictors of PS2. Vascular invasion, absence of teratoma, and a short interval between orchiectomy and RPLND indicated increased risk of relapse in PS1 patients. Vascular invasion, normal Pre-AFP, absence of teratoma elements, and a short orchiectomy to RPLND interval were predictive of MET. Our results indicate that prognostic factors useful for stratification of CS1 patients with NSGCT to different treatment options may be established.
Collapse
Affiliation(s)
- O Klepp
- Department of Oncology, University Hospitals of Trondheim, Bergen, Norway
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Gundersen S, Kvinnsland S, Klepp O, Lund E, Høst H. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer 1990; 26:45-8. [PMID: 2138477 DOI: 10.1016/0277-5379(90)90255-r] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
One hundred and sixty-six patients with advanced breast cancer previously not treated with chemotherapy for metastatic disease were randomly allocated to 20 mg Adriamycin i.v. weekly (Awkly) as bolus injection or 50 mg 4-epidoxorubicin biweekly over a 3-h infusion time (EPIbiwkly). Of the 149 patients evaluable for response, the response rate was 36% for Awkly vs. 22% for EPIbiwkly (P = 0.10). There was no difference in response duration or survival. The main difference between the two regimens was in toxicity. Seventy per cent of Awkly patients virtually had no side-effects vs. 15% in the EPIbiwkly group. Significant differences in favour of Awkly were observed both for nausea/vomiting and alopecia.
Collapse
|
39
|
|
40
|
Abstract
In two consecutive prospective and randomized studies, very similar response rates (31 and 36% respectively) were obtained for weekly 20 mg doses of doxorubicin among 143 patients with advanced breast cancer. The treatment was well tolerated and most patients had only moderate, if any, complaints about this treatment.
Collapse
Affiliation(s)
- S Gundersen
- Department for Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo
| | | | | | | | | |
Collapse
|
41
|
Fosså SD, Klepp O, Norman N. Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. Br J Urol 1988; 62:449-53. [PMID: 2850071 DOI: 10.1111/j.1464-410x.1988.tb04395.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The serum FSH levels were analysed in 24 testicular cancer patients 3 to 9 years after intensive chemotherapy. Sperm cell counts were performed in 12 patients. In all cases a temporary medical castration had been achieved during intensive chemotherapy by the use of medroxyprogesterone acetate (MPA) (500 mg daily per os). The hormone treatment was initiated on day 1 of the first chemotherapy cycle. Thirteen additional patients did not receive this hormone treatment but were treated by similar chemotherapy. The latter patients served as a control group. There was a tendency towards higher FSH levels in the MPA-treated patients than in the controls. Following treatment, serum testosterone was significantly lower in patients who had received MPA during their intensive chemotherapy than in the controls. There was no difference between the groups with regard to recovery of sperm cell production after chemotherapy. An MPA-induced medical castration during intensive chemotherapy in testicular cancer patients is ineffective in protecting the remaining testis against treatment-induced damage to spermatogenesis, at least if hormone treatment is started simultaneously with chemotherapy.
Collapse
Affiliation(s)
- S D Fosså
- Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo
| | | | | |
Collapse
|
42
|
Abstract
A new program package (PharmCalc) has been developed for the calculation of basic pharmacokinetic parameters (half-time, systemic clearance, renal clearance, AUC, volume of distribution, CSF/serum distribution ratio) of methotrexate (MTX). The program helps in the early recognition of patients at risk for toxicity and calculates the dosage of folinic acid rescue adjusted to the serum levels of MTX. The program offers a standardized and automated evaluation procedure for MTX pharmacokinetics and provides an easy-to-use tool for further research in this field. The concept and routines of the program are described.
Collapse
Affiliation(s)
- J D Borsi
- Department of Pediatrics, Medical Faculty, University of Trondheim, Norway
| | | | | |
Collapse
|
43
|
Fosså SD, Aass N, Kaalhus O, Klepp O, Tveter K. Long-term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy. Cancer 1986; 58:2600-5. [PMID: 3022908 DOI: 10.1002/1097-0142(19861215)58:12<2600::aid-cncr2820581208>3.0.co;2-d] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Forty-three of 79 patients treated for clinically metastatic germ cell cancer survived for a median of 66 months (range, 52-83). In patients without previous chemotherapy the 5-year survival rate was 69%, whereas only 32% of patients with prior chemotherapy survived for 5 years. Limited disease, complete clinical response, histopathologically proven postchemotherapy tumor necrosis or complete resectability of a posttreatment mature teratoma indicated a favorable prognosis in patients without prior chemotherapy. Only 20% to 30% of the patients with less than a clinical complete response or with posttreatment residual malignant tumor can be salvaged by second line therapy. Posttreatment mature teratoma should be resected completely whenever possible, as this condition may lead to reactivation of the malignancy even after several years. Raynaud-like phenomena and/or gastrointestinal problems are the main long-term sequel (10%-15%) after modern multimodality treatment of advanced germ cell cancer (fertility-related problems are not considered here). In the majority of surviving patients, the lifestyle seems unaffected by the previous intensive treatment, evaluated about 5 years after discontinuation of all therapy.
Collapse
|
44
|
Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986; 22:1431-4. [PMID: 3595668 DOI: 10.1016/0277-5379(86)90075-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
In a prospective randomised study 128 patients with advanced breast cancer were treated either with Adriamycin (20 mg/week) or vincristine, Adriamycin and cyclophosphamide (VAC). An objective response was obtained in 31 and 35% of patients in the two groups. There was no significant difference with regard to duration of response or survival. Weekly low dose Adriamycin was well tolerated. When subjective side effects occurred, they were usually slight and transient. In approx. 40% of the patients no side-effects at all were observed. Eight per cent had alopecia requiring a wig. Only slight myelosuppression could be seen in a few patients and this had no practical implications. Most or all of VAC patients experienced severe toxicity with regard to nausea, vomiting and alopecia. Also myelosuppression was more pronounced among VAC patients. It is concluded that weekly doses of Adriamycin as single agent therapy for advanced breast cancer is as effective as the VAC combination delivered every third week, with considerably less toxicity.
Collapse
|
45
|
Lote K, Klepp O, Reitan JB. [Radioactive fallout after reactor accidents and nuclear weapons testing]. Tidsskr Nor Laegeforen 1986; 106:1836-40. [PMID: 3764861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
46
|
Abrahamsen AF, Klepp O, Fosså SD, Sønstevold A. Transient vinblastine-induced thrombocytopenia during chemotherapy with vinblastine, cis-platinum and bleomycin. Scand J Haematol 1986; 37:44-9. [PMID: 2429363 DOI: 10.1111/j.1600-0609.1986.tb01770.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
An early, transient drop in peripheral blood platelets to a mean nadir value of 49% (range 31-83%) of the pretreatment value was seen in 31 patients during chemotherapy with cis-platinum, vinblastine and bleomycin (PVB). The mean number of platelets dropped by 22% during the first 24 h after the start of chemotherapy, nadir value was seen after 3 d, with recovery to 107% of pretreatment level on d 14-15. Platelet survival studies during PVB chemotherapy showed shortened platelet survival time and indicated increased destruction of platelets. Identical patterns of early, transient thrombocytopenia were seen in 6 patients treated with vinblastine only. The early fall in circulating platelets did not predict subsequent serious thrombocytopenia. There were no bleeding episodes in the 37 patients studied here, but the early thrombocytopenia seen after vinblastine therapy may possibly be of clinical importance in critically ill patients at risk for bleeding episodes. In rats, an early drop in circulating platelets occurred after a high dose of vinblastine, but not after bleomycin. Addition of bleomycin to vinblastine did not increase the vinblastine-induced thrombocytopenia. It is concluded that the early drop in peripheral blood platelets during chemotherapy with PVB is due to vinblastine.
Collapse
|
47
|
Unsgaard G, Johnsen D, Ringkjøb R, Klepp O. [Treatment of brain metastases]. Tidsskr Nor Laegeforen 1985; 105:738-41. [PMID: 4012680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
48
|
Mella O, Følling Elgjo R, Isaksen H, Klepp O. [Levonantradol as an antiemetic in cancer chemotherapy]. Tidsskr Nor Laegeforen 1984; 104:2320-2. [PMID: 6523465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
49
|
Steffensrud S, Erichsen H, Røysland P, Halvorsen TB, Klepp R, Klepp O, Wünsch E, Petersen H. Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study. Scand J Gastroenterol 1984; 19:909-15. [PMID: 6085189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Secretin and cholecystokinin (CCK) have trophic effects on the pancreas and may therefore have a place in the treatment of pancreatic cancer. The present study was performed to examine whether these hormones may cause harm in patients with pancreatic cancer receiving cytostatics. The cytostatics were 5-fluorouracil, adriamycin, and mitomycin C(FAM). Secretin plus Thr28Nle31CCK25-33, in doses stimulating pancreatic secretion to about 60% of maximal, were given as a continuous 6-day intravenous infusion just before (four patients) or immediately after (five patients) starting treatment with FAM. Five patients received FAM only. When considering symptoms, laboratory findings, abdominal CT scans, and survival, no evidence was found that secretin and CCK may cause serious or unpleasant side effects in patients with pancreatic cancer receiving cytostatics.
Collapse
|
50
|
Wiig JN, Klepp O, Haugen OA. [Conservative surgery of breast cancer. Is there a therapeutic alternative also in Norway?]. Tidsskr Nor Laegeforen 1984; 104:1387-9. [PMID: 6474419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|